|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | C07K 16/22 | |
| C07K 16/00 | |||
| C07K 16/46 | |||
| A61K 39/385 | |||
| A61K 39/395 | |||
| A61P 35/00 | |||
| C12N 5/20 | |||
| G01N 33/577 | |||
| C12N 15/13 | |||
| A61K 47/48 | |||
| G01N 33/68 |
| (11) | Patento numeris | 2272869 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10011651.6 |
| Europos patento paraiškos padavimo data | 2002-10-11 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-01-12 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2013-11-20 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 328604 P | 2001-10-11 | US | |
| 269805 | 2002-10-10 | US |
| (72) |
Oliner, Jonathan Daniel, US
|
| (73) |
Amgen Inc.,
One Amgen Center Drive, Thousand Oaks, CA 91320-1799,
US
|
| (54) | Angiopoietin-2 specific binding agents |
| Angiopoietin-2 specific binding agents |